Wedbush Reaffirms “Outperform” Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a note issued to investors on Wednesday,RTT News reports. They presently have a $18.00 target price on the stock, down from their previous target price of $21.00. Wedbush’s price target would suggest a potential upside of 286.68% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Morgan Stanley dropped their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday, March 5th. Bank of America cut shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a research report on Tuesday, April 22nd. Truist Financial dropped their price objective on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Oppenheimer dropped their price objective on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. Finally, HC Wainwright dropped their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.10.

Y-mAbs Therapeutics Stock Performance

Shares of Y-mAbs Therapeutics stock traded up $0.25 during trading on Wednesday, reaching $4.66. The company’s stock had a trading volume of 51,850 shares, compared to its average volume of 310,882. The business’s fifty day moving average price is $4.39 and its 200-day moving average price is $6.52. The firm has a market cap of $210.80 million, a price-to-earnings ratio of -8.62 and a beta of 0.53. Y-mAbs Therapeutics has a one year low of $3.55 and a one year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. Sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Buying and Selling

In related news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its stake in shares of Y-mAbs Therapeutics by 10.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after buying an additional 2,854 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after purchasing an additional 4,163 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after purchasing an additional 1,903 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Y-mAbs Therapeutics by 1.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock valued at $2,228,000 after purchasing an additional 4,963 shares during the period. Finally, AlphaQuest LLC raised its holdings in shares of Y-mAbs Therapeutics by 6,911.6% in the 4th quarter. AlphaQuest LLC now owns 27,135 shares of the company’s stock valued at $212,000 after purchasing an additional 26,748 shares during the period. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.